ENDRA LIFE SCIENCES INC (NDRA) Stock Fundamental Analysis

NASDAQ:NDRA • US29273B5003

3.86 USD
+0.11 (+2.93%)
At close: Feb 24, 2026
3.86 USD
0 (0%)
Pre-Market: 2/25/2026, 4:00:05 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

Taking everything into account, NDRA scores 2 out of 10 in our fundamental rating. NDRA was compared to 185 industry peers in the Health Care Equipment & Supplies industry. NDRA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. NDRA does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year NDRA has reported negative net income.
  • In the past year NDRA has reported a negative cash flow from operations.
  • In the past 5 years NDRA always reported negative net income.
  • NDRA had a negative operating cash flow in each of the past 5 years.
NDRA Yearly Net Income VS EBIT VS OCF VS FCFNDRA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -407.68%, NDRA is doing worse than 94.05% of the companies in the same industry.
  • NDRA's Return On Equity of -4671.65% is on the low side compared to the rest of the industry. NDRA is outperformed by 87.57% of its industry peers.
Industry RankSector Rank
ROA -407.68%
ROE -4671.65%
ROIC N/A
ROA(3y)-186.58%
ROA(5y)-157.26%
ROE(3y)-276.15%
ROE(5y)-220.55%
ROIC(3y)N/A
ROIC(5y)N/A
NDRA Yearly ROA, ROE, ROICNDRA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for NDRA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NDRA Yearly Profit, Operating, Gross MarginsNDRA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20K -40K -60K -80K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • The number of shares outstanding for NDRA has been increased compared to 1 year ago.
  • NDRA has more shares outstanding than it did 5 years ago.
  • There is no outstanding debt for NDRA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
NDRA Yearly Shares OutstandingNDRA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M
NDRA Yearly Total Debt VS Total AssetsNDRA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

  • NDRA has an Altman-Z score of -88.99. This is a bad value and indicates that NDRA is not financially healthy and even has some risk of bankruptcy.
  • NDRA's Altman-Z score of -88.99 is on the low side compared to the rest of the industry. NDRA is outperformed by 94.59% of its industry peers.
  • There is no outstanding debt for NDRA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -88.99
ROIC/WACCN/A
WACCN/A
NDRA Yearly LT Debt VS Equity VS FCFNDRA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M -10M

2.3 Liquidity

  • NDRA has a Current Ratio of 1.31. This is a normal value and indicates that NDRA is financially healthy and should not expect problems in meeting its short term obligations.
  • NDRA has a worse Current ratio (1.31) than 79.46% of its industry peers.
  • NDRA has a Quick Ratio of 1.31. This is a normal value and indicates that NDRA is financially healthy and should not expect problems in meeting its short term obligations.
  • With a Quick ratio value of 1.31, NDRA is not doing good in the industry: 63.78% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.31
Quick Ratio 1.31
NDRA Yearly Current Assets VS Current LiabilitesNDRA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • NDRA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 98.07%, which is quite impressive.
EPS 1Y (TTM)98.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%77.99%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • NDRA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 41.15% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y98.9%
EPS Next 2Y41.15%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NDRA Yearly Revenue VS EstimatesNDRA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2021 2022 2026 500K 1M
NDRA Yearly EPS VS EstimatesNDRA Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 -20K -40K -60K -80K

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for NDRA. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NDRA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NDRA Price Earnings VS Forward Price EarningsNDRA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NDRA Per share dataNDRA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6 -8 -10

4.3 Compensation for Growth

  • NDRA's earnings are expected to grow with 41.15% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.15%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • NDRA does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ENDRA LIFE SCIENCES INC

NASDAQ:NDRA (2/24/2026, 8:00:01 PM)

Premarket: 3.86 0 (0%)

3.86

+0.11 (+2.93%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-14
Earnings (Next)03-30
Inst Owners1.8%
Inst Owner Change449.34%
Ins Owners12.6%
Ins Owner Change56.04%
Market Cap4.52M
Revenue(TTM)N/A
Net Income(TTM)-8.01M
Analysts82.86
Price Target30.6 (692.75%)
Short Float %7.34%
Short Ratio0.96
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)10.28%
Min EPS beat(2)-5.58%
Max EPS beat(2)26.15%
EPS beat(4)2
Avg EPS beat(4)-2.48%
Min EPS beat(4)-83.84%
Max EPS beat(4)53.36%
EPS beat(8)5
Avg EPS beat(8)19.38%
EPS beat(12)8
Avg EPS beat(12)16.28%
EPS beat(16)11
Avg EPS beat(16)13.11%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-21.05%
EPS NQ rev (1m)0%
EPS NQ rev (3m)36.92%
EPS NY rev (1m)0%
EPS NY rev (3m)11.9%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 26.35
P/tB 26.35
EV/EBITDA N/A
EPS(TTM)-13.36
EYN/A
EPS(NY)-4.71
Fwd EYN/A
FCF(TTM)-4.36
FCFYN/A
OCF(TTM)-4.35
OCFYN/A
SpS0
BVpS0.15
TBVpS0.15
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -407.68%
ROE -4671.65%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-186.58%
ROA(5y)-157.26%
ROE(3y)-276.15%
ROE(5y)-220.55%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr -21.79%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.31
Quick Ratio 1.31
Altman-Z -88.99
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)87.27%
Cap/Depr(5y)76.7%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)98.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%77.99%
EPS Next Y98.9%
EPS Next 2Y41.15%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-5.78%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y51.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y51.37%
OCF growth 3YN/A
OCF growth 5YN/A

ENDRA LIFE SCIENCES INC / NDRA FAQ

What is the fundamental rating for NDRA stock?

ChartMill assigns a fundamental rating of 2 / 10 to NDRA.


What is the valuation status for NDRA stock?

ChartMill assigns a valuation rating of 1 / 10 to ENDRA LIFE SCIENCES INC (NDRA). This can be considered as Overvalued.


What is the profitability of NDRA stock?

ENDRA LIFE SCIENCES INC (NDRA) has a profitability rating of 0 / 10.


How financially healthy is ENDRA LIFE SCIENCES INC?

The financial health rating of ENDRA LIFE SCIENCES INC (NDRA) is 5 / 10.